Rhythm Pharmaceuticals (RYTM) News Today

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) saw its shares move as investors digest a flurry of analyst actions, clinical updates and insider trades. Strong trial data and multiple price‐target upgrades bolstered bullish sentiment, while sizable insider sales and a recent equity offering tempered enthusiasm.

• Positive Sentiment: Wells Fargo & Company raised its price target on RYTM to $129 and maintained an “overweight” rating, signaling substantial upside potential. Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
• Positive Sentiment: Oppenheimer boosted its objective from $76 to $110 and assigned an “outperform” rating, reflecting increasing confidence in RYTM’s pipeline. Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $110.00 Price Target at Oppenheimer
• Positive Sentiment: Bank of America lifted its target from $73 to $95 and kept a “buy” rating, pointing to continued confidence in RYTM’s mid‐ and long‐term growth. Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $95.00 Price Target at Bank of America
• Positive Sentiment: Goldman Sachs initiated coverage with a “buy” rating and a $97 target, underscoring optimism about RYTM’s commercial‐stage portfolio. Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Analysts at The Goldman Sachs Group
• Positive Sentiment: A mid‐stage study showed bivamelagon delivered statistically significant and clinically meaningful BMI and hunger reductions in acquired hypothalamic obesity, validating RYTM’s oral MC4R agonist approach. Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

• Neutral Sentiment: Leerink Partners reiterated a “Strong-Buy” rating and updated EPS forecasts for Q2–Q4 2025, keeping full-year estimates largely unchanged. Analysts Issue Forecasts for RYTM Q2 Earnings
• Neutral Sentiment: Rhythm priced an upsized public offering of 2,058,824 shares at $85.00 each (plus a 30-day option for 308,823 additional shares), aiming to fund late-stage development and commercial activities. Rhythm Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
• Neutral Sentiment: July short interest remained effectively zero, indicating minimal bearish positioning and tight days-to-cover at 0.0 days. (SEC filings)

• Negative Sentiment: Multiple insiders—including the CFO, CAO and senior executives—sold large stakes on July 9, trimming holdings by up to 80%, which may raise questions about insider conviction. (SEC filings)
• Negative Sentiment: Some brokerages set more conservative price targets (e.g., $77.31), suggesting valuation concerns among a subset of analysts. Brokerages Set Rhythm Pharmaceuticals, Inc. PT at $77.31